Is amiloride a promising cardiovascular medication to persist in the COVID-19 crisis?
Drug Discov Ther
; 14(5): 256-258, 2020 Nov 04.
Article
in English
| MEDLINE | ID: covidwho-895583
ABSTRACT
In the ongoing coronavirus diseases-2019 (COVID-19) crisis that caused immense suffering and deaths, the choice of therapy for the prevention and life-saving conditions must be based on sound scientific evidence. Uncertainty and apprehension are exacerbated in people using angiotensin-converting enzyme (ACE) inhibitors to control their comorbidities such as hypertension and diabetes. These drugs are reported to result in unfavorable outcome as they tend to increase the levels of ACE2 which mediates the entry of SARS-CoV-2. Amiloride, a prototypic inhibitor of epithelial sodium channels (ENaC) can be an ideal candidate for COVID-19 patients, given its ACE reducing and cytosolic pH increasing effects. Moreover, its potassium-sparing and anti-epileptic activities make it a promising alternative or a combinatorial agent.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Pneumonia, Viral
/
Coronavirus Infections
/
Respiratory Mucosa
/
Virus Internalization
/
Epithelial Sodium Channel Blockers
/
Betacoronavirus
/
Amiloride
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Drug Discov Ther
Year:
2020
Document Type:
Article
Affiliation country:
Ddt.2020.03070
Similar
MEDLINE
...
LILACS
LIS